Acurx Pharmaceuticals Advances Ibezapolstat Toward Phase 3
STATEN ISLAND, N.Y., August 14, 2026 Acurx Pharmaceuticals, Inc. reported its second-quarter 2026 financial results and provided a business...
C difficile Infection
Advertisement
Genprex and Roche Diagnostics Advance TROP2 Biomarker Strategy
Austin, Texas, August 3, 2026 Genprex, Inc. announced a collaboration with Roche Diagnostics to conduct biomarker assay validation studies...
Keenova Publishes New XIAFLEX Data in Peyronie’s Disease
Dublin, Ireland, August 3, 2026 Keenova Therapeutics plc announced the publication of a new manuscript evaluating XIAFLEX® (collagenase clostridium...
Acurx Gains FDA Guidance for Ibezapolstat Phase 3 Program
Staten Island, New York, August 3, 2026 Acurx Pharmaceuticals, Inc. announced further regulatory guidance from the U.S. Food and...
Advertisement
